Press release
Eosinophilic Esophagitis Treatment Market Size in the 7MM was ~USD 1,800 million in the 2023, which is expected to grow by 2034, estimates DelveInsight
Unlock key insights into the Eosinophilic Esophagitis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Eosinophilic Esophagitis Market Size [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Eosinophilic Esophagitis Market Report
* In June 2025, Sanofi announced a Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.
* In June 2025, Dr. Falk Pharma GmbH conducted a study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
* In the 7MM, the US accounted for the highest Eosinophilic Esophagitis Diagnosed Prevalent Cases in 2023, with around 445,000 cases; these numbers are expected to increase during the forecast period.
* Eosinophilic Esophagitis predominantly affected males, with approximately 290,000 males diagnosed compared to 156,000 females in 2023 in the US.
* In the 7MM, individuals over the age of 18 were the most affected by Eosinophilic Esophagitis, with approximately 156,000 cases reported in 2023.
* The leading Eosinophilic Esophagitis Companies such as Bristol Myers Squibb (BMS), Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Dr. Falk Pharma GmbH, Regeneron Pharmaceuticals, Sanofi, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, and others.
* Promising Eosinophilic Esophagitis Pipeline Therapies such as Mepolizumab, Dupilumab, Etrasimod, Tezepelumab, Barzolvolimab, NDX-3315 and NDX-3324 and others.
Stay ahead in the competitive landscape of the Eosinophilic Esophagitis Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Eosinophilic Esophagitis Treatment Market Size [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eosinophilic Esophagitis Epidemiology Segmentation in the 7MM
* Total Diagnosed Prevalent Cases of Eosinophilic Esophagitis
* Gender-specific Cases of Eosinophilic Esophagitis
* Age-specific Cases of Eosinophilic Esophagitis
* Treated Cases of Eosinophilic Esophagitis
Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ Eosinophilic Esophagitis Prevalence [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eosinophilic Esophagitis Marketed Drugs
* DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
DUPIXENT, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the signaling of the Interleukin-4 (IL-4) and Interleukin-13 (IL-13) pathways and is not an immunosuppressant. It is approved for the treatment of DUPIXENT, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the signaling of the Interleukin-4 (IL-4) and Interleukin-13 (IL-13) pathways and is not an immunosuppressant.
Eosinophilic Esophagitis Emerging Drugs
* Cendakimab (CC-93538/RPC4046): Bristol Myers Squibb (BMS)
Cendakimab/RPC4046/CC-93538 is a recombinant humanized, high affinity, selective, anti-IL-13 mAb. RPC4046 binds an IL-13 epitope that prevents its binding to both IL-13R (alpha) 1 and IL-13R (alpha) 2, providing potential efficacy and/or safety advantages. The drug has been granted ODD for the treatment of EoE by the US FDA. In the Phase II study, RPC4046 demonstrated positive results. Currently, the company is conducting two Phase III Eosinophilic Esophagitis clinical trials to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with EoE.
* TEZSPIRE (Tezepelumab) : AstraZeneca/Amgen
TEZSPIRE (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of TSLP. This key epithelial cytokine sits at the top of multiple inflammatory cascades. It is critical in the initiation and persistence of allergic, eosinophilic, and other types of airway inflammation associated with severe asthma, including airway hyperresponsiveness. TEZSPIRE acts at the top of the inflammation cascade and has the potential to help address a broad population of severe asthma patients irrespective of biomarker levels.
Discover the future of Eosinophilic Esophagitis Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Eosinophilic Esophagitis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Eosinophilic Esophagitis Market Outlook
The Eosinophilic Esophagitis Market is driven by significant unmet needs, particularly in the development of novel treatments and the establishment of comprehensive guidelines for adolescents and adults. Current treatments, like proton pump inhibitors and corticosteroids therapy, manage symptoms but come with serious side effects due to high steroid dosages. Although in recent years therapies like DUPIXENT, EOHILIA and JOrveza got approved in 7MM countries but still there is huge scope for emerging.
Eosinophilic Esophagitis Companies
Bristol Myers Squibb (BMS), Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Dr. Falk Pharma GmbH, Regeneron Pharmaceuticals, Sanofi, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, and others.
Scope of the Eosinophilic Esophagitis Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Eosinophilic Esophagitis Companies- Bristol Myers Squibb (BMS), Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Dr. Falk Pharma GmbH, Regeneron Pharmaceuticals, Sanofi, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, and others.
* Eosinophilic Esophagitis Pipeline Therapies- Mepolizumab, Dupilumab, Etrasimod, Tezepelumab, Barzolvolimab, NDX-3315 and NDX-3324 and others.
* Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis Current Marketed and Eosinophilic Esophagitis Emerging Therapies
* Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers
* Eosinophilic Esophagitis Unmet Needs, KOL's views, Analyst's views, Eosinophilic Esophagitis Market Access and Reimbursement
Explore the dynamics of the Eosinophilic Esophagitis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Eosinophilic Esophagitis Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
1. Key Insights
2. Eosinophilic Esophagitis Market Report Introduction
3. Eosinophilic Esophagitis Market Overview at a Glance
4. Eosinophilic Esophagitis Methodology
5. Eosinophilic Esophagitis Executive Summary
6. Key Events
7. Disease Background and Overview
8. Eosinophilic Esophagitis Treatment
9. Treatment Guidelines
10. Eosinophilic Esophagitis Epidemiology and Patient Population
11. Patient Journey
12. Eosinophilic Esophagitis Marketed Therapies
13. Eosinophilic Esophagitis Emerging Therapies
14. Eosinophilic Esophagitis Market Analysis
15. KOL Views
16. Eosinophilic Esophagitis SWOT Analysis
17. Eosinophilic Esophagitis Unmet Needs
18. Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-esophagitis-treatment-market-size-in-the-7mm-was-usd-1800-million-in-the-2023-which-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eosinophilic Esophagitis Treatment Market Size in the 7MM was ~USD 1,800 million in the 2023, which is expected to grow by 2034, estimates DelveInsight here
News-ID: 4080430 • Views: …
More Releases from ABNewswire
From Corporate Geologist to Animal Advocate: The Inspiring Story Behind Crazy K …
Crazy K Farm Pet and Poultry Products emerged from one woman's courageous decision to prioritize family over career when a corporate ultimatum forced an impossible choice. Today, the company holds 19 patents with one pending, plus nine trademarks, and supports over 200 rescued animals through its 501(c)(3) sanctuary. As the year ends and families reflect on what matters most, the founder's journey offers inspiration for the new year ahead.
Behind every…
How Sweetwater Labs Built a Natural Skincare Brand on Efficacy, Service, and Cus …
Sweetwater Labs has emerged as a standout in the natural skincare industry by prioritizing product effectiveness and exceptional customer service over marketing hype. The brand's approach has created a loyal community of customers who return repeatedly and enthusiastically recommend products to others seeking natural solutions.
In a beauty industry dominated by aggressive marketing and influencer partnerships, Sweetwater Labs has taken a different path to success. The brand has built its reputation…
Standard Modulus Carbon Fiber Market Growth Overview, Facts & Figures, Segmentat …
The Standard Modulus Carbon Fiber Market is witnessing steady growth, supported by rising demand from aerospace, automotive, wind energy, and construction industries. Key players such as Toray Industries, Hexcel Corporation, Teijin Limited, Mitsubishi Chemical Group, and SGL Carbon are focusing on capacity expansion, cost optimization, and performance enhancement to strengthen their market position. I prefer this response
The standard modulus carbon fiber market is projected to reach USD 4.50 billion by…
Linux-VServer.org Celebrates 25 Years of Innovation with Launch of v3: A Revolut …
BERLIN, GERMANY - December 25, 2025 - Linux-VServer.org [http://linux-vserver.org], the pioneer open-source project known for defining the standards of Linux server virtualization for over two decades, is proud to announce the historic launch of its v3 release. Marking a bold strategic evolution, the project has expanded beyond its virtualization roots to introduce a comprehensive MDM software designed specifically for the modern complexities of Ubuntu, Debian, CentOS, and Arch Linux environments.
For…
More Releases for Eosinophilic
Eosinophilic Esophagitis Market to Surge to USD 4.1 Billion by 2034
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus, characterized by eosinophil infiltration, difficulty swallowing, food impaction, and chest pain. Once considered rare, EoE has now emerged as one of the most common causes of dysphagia in children and adults, particularly in developed nations. Strong associations with allergic conditions such as asthma, eczema, and food allergies underscore its complex immunological nature.
Download Full PDF Sample Copy of Market…
Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2030
The eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Esophagitis Pipeline, Clinical Trials Assessment, Emerging Therapie …
DelveInsight's, "Eosinophilic Esophagitis Pipeline Insight" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Eosinophilic Esophagitis research. Learn more about…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Granulomatosis Treatment Market Size and Overview Upto 2028|
The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Eosinophilic Granulomatosis Treatment market. It includes Porter's Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Eosinophilic Granulomatosis Treatment Market. We have provided a deep analysis of the vendor landscape to give…
